Last week, the U.S. Food and Drug Administration (FDA) approved the use of Darzalex Faspro (daratumumab and ...
On July 2, linvoseltamab-gcpt (Lynozyfic; Regeneron) received an accelerated approval from the FDA in relapsed/refractory multiple myeloma (MM), and the most recent update to the National ...
ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO ...
Johnson & Johnson (NYSE:JNJ) received FDA approval for DARZALEX FASPRO in combination with D-VRd. The regimen is approved for adult patients with newly diagnosed multiple myeloma who are ineligible ...
Panelists discuss how NCCN guidelines are expected to incorporate quadruplet-based regimens as reasonable treatment approaches for transplant-ineligible patients, while emphasizing the need for ...
Smoldering multiple myeloma is an asymptomatic, precancerous condition with abnormal plasma cells and elevated monoclonal protein levels. Smoldering multiple myeloma is a complex, intermediary stage ...
Hosted on MSN
The latest on preventing VTE in multiple myeloma
"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...
Common manifestations and complications of multiple myeloma (MM) can include bone complications, hypercalcemia, renal insufficiency, infection, skeletal lesions and anemia. Other less common ...
Hosted on MSN
The Wealth and Complexity of Treatment Options for Relapsed/Refractory Multiple Myeloma
"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this 12-part journey through a disease state ...
2025 MAY 26 (NewsRx) -- By a News Reporter-Staff News Editor at Information Technology Business Daily-- New research on Oncology - Multiple Myeloma is the subject of a report. According to news ...
Please provide your email address to receive an email when new articles are posted on . This one-hour on-demand video learning module features a pair of expert multidisciplinary hematology providers ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results